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Cancer is a multifaceted molecular disorder that is modulated by a combination of genetic, metabolic and signal
transduction aberrations, which severely impair the normal homeostasis of cell growth and death. Accumulating
findings highlight the fact that different genetic alterations, such as mutations in tumor suppressor genes, might be
related to distinct and differential sensitivity to targeted therapies. It is becoming increasingly apparent that a
multipronged approach that addresses genetic milieu (alterations in upstream and/or parallel pathways) eventually
determines the response of individual tumors to therapy. Cancerous cells often acquire the ability to evade death
by attenuating cell death pathways that normally function to eliminate damaged and harmful cells. Therefore
impaired cell death nanomachinery and withdrawal of death receptors from cell surface are some of major
determinants for the development of chemotherapeutic resistance encountered during treatment. It is therefore
essential to emphasize underlying factors which predispose cells to refractoriness against TRAIL mediated cell death
pathway and the relevant regulatory components involved. We bring to limelight the strategies to re-sensitize TRAIL
resistant cells via vitamins to induce apoptosis.Introduction
TRAIL plays an imperative role in host immunosurveil-
lance in opposition to tumor progression, as it triggers
apoptosis of tumor cells but not normal cells, and there-
fore has great therapeutic potential for cancer treatment.
It is a well established fact that TRAIL binds to two cell-
death-inducing (DR4 and DR5) and two decoy (DcR1,
and DcR2) receptors. Various reviews have been written
highlighting role of TRAIL mediated signaling cascade in
prostate cancer [1-3]. Escalating preclinical studies reveal
that the TRAIL ligand can efficiently induce cancer cell
apoptosis. Completed and ongoing Phases I and II clin-
ical trials using TRAIL, represent clinically promising
outcomes exclusive of significant toxicity. To date, re-
search has focused on the patterns of apoptosis induced
by TRAIL and interpreting complex barcodes underlying
TRAIL resistance. Escape of death receptors from cell
surface is equivalent to narrow escape of cancerous cells.
It is becoming progressively more obvious that mem-
brane curvature is no longer viewed simplistically as a
passive outcome of cellular activity. It has been appraised* Correspondence: ammadahmad638@yahoo.com
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reproduction in any medium, provided the orby considerable evidence as an active mode or alterna-
tively a rheostat like switch to create membrane domains
and to organize centres for membrane trafficking. The
mechanism of internalization is instrumental in redistribu-
tion and reshuffling of versatile proteins in cytoplasm and
plasma membrane in normal and cancerous cells. On a lar-
ger scale, membrane curvature occupies a central stage in
growth and division however dysregulation in spatio-tem-
poral pattern underlies cancer progression. This review
untangles complex web of modulators which promote
“duty shift” of the death receptors in the cancerous cells
and the approaches which will counteract their withdrawal
from the cell surface. In the next section we give a detailed
account of Vitamins which are documented to stimulate
the re-establishment of death receptors on plasma mem-
brane and consequently re-sensitizing cancer cells to
TRAIL mediated apoptosis.
Vitamin A and TRAIL: two stepping stones of the TRAIL
Confluence of information suggests that underpinnings
of refractoriness to TRAIL induced apoptosis in malig-
nant cells and normal cells is not entirely understood.
However substantial fraction of data has been added
into the existing web of knowledge with reference to
variety of factors that are present in the tumorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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malignant cells to TRAIL. An emerging paradigm in
cancer chemoprevention is use of natural or biological
substances to reverse, repress or counteract either the
initial phase of carcinogenesis or the progression of
neoplastic cells to cancer. This review provides a
summary of the impact of vitamins on mechanisms
connected with enhancement of TRAIL mediated sig-
naling together with modulation of the apoptotic
(death receptor expression, FLIP, and Bcl-2 or inhibi-
tors of apoptosis (IAP) families) as well as cell signal
transduction cascades.
It is becoming gradually more apparent that all trans
retinoic acid (ATRA) restricted phosphorylation of
FOXO3A in acute promyelocytic leukemia (APL) cells.
The reduction in phosphorylation of FOXO3A resulted
in its re-distribution by consequent shuttling into the
nucleus to stimulate the expression of TRAIL [4].
Detailed investigations unveil the fact that refractoriness
against TRAIL is generated by orchestrated activities of
anti-apoptotic proteins. In accordance with this concept,
recent information suggests that all-trans-retinyl acetate
(RAc) trigger the expression of TRAIL death receptors
and suppresses decoy receptors. Additionally, combina-
torial approach induced apoptosis in APC-deficient pre-
malignant cells without affecting normal cells in vitro
Zhang et al., [5].
Promoter mapping, gel retardation and chromatin
immunoprecipitation assays unraveled the detail that
retinoids induced the expression of TRAIL mainly
through crosstalk with NF-kappaB. However there is a
differential mode of action in combination with etopo-
side, camptothecin or doxorubicin as it antagonized the
apoptosis triggered by the chemotherapeutic drugs.
Discordantly, apoptosis induced by TRAIL was not
antagonized by retinoids [6].
Accumulating evidence suggests that that a combination
treatment with all-trans retinoic acid (ATRA) and TGF-
beta1 leads to remarkable ATRA-induced suppression of
cell proliferation, which is simultaneously accompanied by
repression of ATRA-induced apoptosis in human leukemia
HL-60 cells. Henceforth TGF signal transduction cascade
resulted in dampening apoptosis inducing activity of ATRA
by enhancing expression of c-FLIP(L) protein [7].
It is worth mentioning that retinoic acid (RA) has
antileukemic activity and up-regulates the expression of
TRAIL and its DR4 and DR5 receptors. In a RA-sensitive
cell line PLB985, targeted inhibition of TRAIL blocked
RA-induced apoptosis [8].
It is intriguing to note that in the leukemic blasts of
acute promyelocytic leukemia patients, retinoic-acid-
induced expression of TRAIL caused blast apoptosis.
Therefore, initiation of TRAIL-mediated death signaling
is contributory to the therapeutic value of retinoids[9,10]. Comprehensive analysis dismantled the fact that
many mechanisms accounted for the anticarcinogenic
actions of dietary constituents. Future studies must
converge on multiple intracellular-signal transduction
cascades as common molecular targets for vitamin A.
Vitamin C and TRAIL: it takes two to tango
The antioxidant, vitamin C stimulated perifosine (an
alkylphospholipid tested in phase II clinical trials)-
induced expression of DR4 and DR5 in head and neck
squamous cell carcinoma cells and inhibited the growth
of xenografts [11]. Controversies exist with reference to
role of Vitamin C in induction of apoptosis as it impedes
the elevation of reactive oxygen species (ROS) levels
induced by TRAIL and impairs caspase-8 activation [12].
Consistent with the same interpretation, Vit C abrogated
triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-
28-oate (CDDO-Me) induced apoptosis [13]. In vitro
analysis still is insufficient to provide a detailed concept
of effect of vitamin C on TRAIL mediated signaling cas-
cade and its respective receptors. Moreover, keeping in
view, divergent effects of vitamin C, it will have differential
effects on individuals whose genotype enhances significant
benefit derived from an increased intake of vitamin C
enriched items, and a small segment of the population that
may be disadvantaged. Therefore, large-scale, whole-gen-
ome association studies will surely present a reasonable
understanding of the steps and factors that modulate ma-
chinery of apoptosis.
Vitamin D
Considerable verification suggests that pretreatment with
1,25-dihydroxyvitamin D3 repressed apoptosis induced
by TRAIL and Fas ligand by up-regulating decoy recep-
tor and death receptor 4 and repressing Fas. However
abrogation of death receptor 4 or enforced expression of
Fas attenuated the suppressive effect of 1,25-dihydroxyvi-
tamin [14]. On a parallel note, PEA-15 (phosphoprotein
enriched in astrocytes-15 kD, also known as PED), has
anti-proliferative and anti-apoptotic effects and is tran-
scriptionally triggered by vitamin D(3). Outstandingly,
vitamin D(3) was able to chaperone cells from TRAIL-
induced apoptosis by stimulating the expression of the
PEA-15 [15].
It has recently been explored that TRAIL mediated
apoptosis is impaired by IL-1beta release from macro-
phages. Contrarily, Vitamin D(3) interfered with the re-
lease of IL-1beta from macrophages thus re-sensitizing
tumor cells to TRAIL-induced apoptosis [16]. Center of
attention in future work should be on identifying 'driver'
molecular defects of oncogenic pathways that can be
targeted therapeutically, discovering predictive biomar-
kers for treatment response, and prioritizing promising
drugs to speed up their approval.
Farooqi et al. Cancer Cell International 2012, 12:22 Page 3 of 9
http://www.cancerci.com/content/12/1/22An enhanced appreciation of the molecular biology of
cancer cell growth and survival and the role of the
microenvironment in supporting the survival of cancer
cells in future will result in identification of additional
distinct roles of vitamin D in regulating cellular activity.
Vitamin E: travel guide or pathfinder
It is perceptible that α-TOS and hrTRAIL in combin-
ation act with remarkable synergy to induce apoptosis in
breast cancer cells. Moreover, α-TOS repressed the ex-
pression of FLIP and c-IAP1 in erbB2-positive cells [17].
In agreement with the same conception, Vitamin E
derivative RRR-α-tocopherol ether-linked acetic acid
analog (α-TEA) stimulated the expression of TRAIL and
DR5and considerably repressed levels of antiapoptotic
factor, c-FLIP L [18,19]. Further insights into the
mechanisms indicated that alpha-TEA induced suppres-
sion of c-FLIP (L) protein level was triggered by JNK/
CHOP/DR5 loop via a JNK dependent Itch E3 ligase ubi-
quitination that promoted JNK/CHOP/DR5 amplifica-
tion loop by restricting c-FLIP's inhibition of caspase-8
[20].
Another interesting finding suggests that Tocotrienol
(T3), an unsaturated vitamin E but not tocopherol,
induced transcriptional up-regulation of the death recep-
tor (DR)-4 and DR5 via enhanced production of reactive
oxygen species and augmented activation of ERK1 [21].
Analogously, treatment of human MDA-MB-231 and
MCF-7 cells with γ-T3 resulted in activation of JNK and
p38 MAPK, and upregulated DR5 and C/EBP homolo-
gous protein (CHOP). Insightful approaches suggested
that DR5 was transcriptionally regulated by CHOP after
γ-T3 treatment [22].
It is becoming progressively more appreciable that
alpha-tocopheryl succinate (alpha-TOS) re-sensitizes
TRAIL-resistant malignant mesothelioma (MM) cells to
TRAIL-induced apoptosis. This transformation of TRAIL
refractory (MM) cells to TRAIL sensitive (MM) cells
occurs in a p53-dependent manner as p53competent
MM cells are responsive to sensitization however, p53de-
ficient counterparts are insensitive [23]. Furthermore,
malignant(MM) and non-malignant counterparts (Met-
5A) have differential responsiveness to alpha-tocopheryl
succinate (alpha-TOS) and TRAIL. Molecular
approaches suggest that MM cells are susceptible to
alpha-TOS and less to TRAIL, whereas Met-5A cells are
susceptible to TRAIL and resistant to alpha-TOS [24] .
High throughput technologies indicated that alpha-TOS
and TRAIL acted synergism to kill MM cells via mito-
chondrial pathway, and were nontoxic to nonmalignant
mesothelial cells [25]. It is attention-grabbing that mito-
chondrion is instrumental in apoptosis induced by alpha-
tocopheryl succinate as mtDNA-deficient cells display
resistance to alpha-TOS [26].Mounting data suggests that tocotrienol-induced cas-
pase-8 activation and apoptosis in malignant (+)SA
mammary epithelial cells is irrespective of the activation
of death receptors and is dependent on suppression of
the PI3K/PDK/Akt signal transduction cascade and
succeeding repression in FLIP expression [27].
It is becoming more and more evident that exposure
of the cells to TRAIL results in transient activation of
NF-kappaB, a process that is suppressed by cell pretreat-
ment with alpha-TOS. alpha-TOS re-sensitizes cells to
TRAIL killing, through repression of NF-kappaB activa-
tion [28].
It is worth mentioning that alpha-TOS is nontoxic to
normal cells however simultaneously triggers apoptosis
in p53 deficient and p21deficient cancer cells [29].
It is contemplating to note that multiple gene variants
that have small to moderate individual phenotypic effects
contribute to the overall progression of cancer. A par-
ticular individual's level of cancer susceptibility and re-
currence depends on interactions between
environmental factors and a wide range of modifier
genes, which systematically impact derailed cellular ac-
tivities and resistance against a multiple therapeutic
interventions especially TRAIL. The latest genome-wide
association studies in large cohorts of patients with dif-
ferent cancers provided new insights into the patho-
physiology of these molecular disorders and have
suggested contribution of previously unsuspected mo-
lecular signaling pathways. Additionally, model studies
have identified supplementary susceptibility genes for in-
ducing resistance against TRAIL mediated apoptosis. We
therefore developed a roadmap of various signaling path-
ways which were contributory in driving or suppressing
carcinogenesis alongwith effect of vitamins at nanoscale
level. Next, we discuss the factors governing sequestra-
tion of death receptors off plasma membrane.
Death receptors internalization: gatekeepers are hijacked
It is praiseworthy that new techniques are deepening our
insight into the dynamics of membrane organization.
Here, we discuss how the field of internalization and
degradation of death receptors has matured and present
growing model in which membranes are occupied
by fluctuating nanoscale assemblies of sphingolipids,
cholesterol and proteins that can be stabilized into plat-
forms that are important in TRAIL mediated signaling
and membrane trafficking. TRAIL mediated signaling
occurs by various mechanisms, which can be divided
into those that are clathrin dependent and those that are
clathrin independent Figure 1.
Emerging evidence suggests that stable TRAIL-resistant
sub-population of the metastatic colon cancer cell line
LIM6-TR displays an increased cell-surface expression of
galectin-3. Interestingly, protein purification strategies
Figure 1 Modes of internalization of death receptors.
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tated with death receptors. Targeted inhibition of galectin-
3 re-sensitized resistant cells to TRAIL and facilitated
TRAIL-mediated endocytosis of TRAIL/death receptors
complexes [30]. It is getting gradually more obvious that
ARAP1 knockdown drastically hampers cell surface
expression of DR4 in several tumor cell lines and represses
their TRAIL-induced death. Laboratory investigations
suggested that transfected ARAP1 co-purified with DR4
and co-occured with it in the endoplasmic reticulum/
Golgi, at the cytoplasmic membrane and in early endo-
somes of TRAIL-treated cells [31].
Additionally, TRAIL cytotoxicity in hepatocellular car-
cinoma cells is triggered by lysosomal permeabilization.
Death receptors behave in a differential manner in
terms of trafficking to lysosomes as DR5 complex
under go immediate endocytosis upon ligand stimula-
tion, while DR4 complex is not proficiently interna-
lized. Upon TRAIL treatment, DR5 co-existed with
lysosomes following internalization and abrogation of
DR5 trafficking to lysosomes in Rab7 deficient cells
also repressed TRAIL-mediated lysosomal disruption
and apoptosis [32]. Emerging line of evidence indi-
cated that PRMT5 selectively interacted with death
receptor 4 and death receptor 5. Gene silencing strat-
egies suggested that PRMT5 abrogation sensitized
various cancer cells to TRAIL. PRMT5 effectively
modulated TRAIL-induced activation of inhibitor of
kappaB kinase (IKK) and nuclear factor-kappaB (NF-
kappaB), thus stimulating the expression of several
NF-kappaB target genes [33].Moreover, in MDA-MB-231 breast cancer cells, endo-
cytosed DR4 is cleaved in a caspase-dependent manner.
It is worth mentioning that receptor internalization does
not inhibit caspase activation, instead stimulates apop-
tosis after TRAIL treatment. Consistent with the same
concept, it is obvious that TRAIL-induced receptor
endocytosis suppresses its pro-apoptotic potential [34].
Besides, impairment of endocytosis or disruption of
clathrin-dependent endocytosis signaling components
(adaptor protein 2 and clathrin) recapitulates cell surface
appearance of the death receptors and sensitize TRAIL-
resistant cells to TRAIL-induced apoptosis. Structural
overview of DR4 indicates that endocytosis is modulated
by its cytoplasmic domain EAQC(337)LL. Therefore
unquestionably clathrin-mediated endocytosis pathway
could be a prospective target for therapeutics to circum-
vent tumor resistance to TRAIL receptor-targeted
therapies [35].
It is becoming sequentially more apparent that death
receptors trigger selective destruction of the clathrin-
dependent endocytosis nano- machinery. DR stimula-
tion initiated instantaneous, caspase-mediated cleavage
of clathrin-pathway apparatus, impeding retrieval of
cargo protein transferrin. Analogously, caspases cleaved
the clathrin adaptor subunit AP2alpha between charac-
teristically discrete domains, while effector caspases pro-
cessed clathrin's heavy chain [36].
Escalating evidence suggests that COX-2 abrogation
sensitizes human colon carcinoma cells to TRAIL
induced apoptosis by enhancing assembly of the TRAIL
receptor DR5 at the cell surface. Simultaneously, it is
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signaling complex components into cholesterol-rich
and ceramide-rich domains known as caveolae. This
progression is dependent on accumulation of arachidonic
acid and consequent activation of acid sphingomyelinase
for the generation of ceramide within the plasma mem-
brane outer leaflet [37].
It is intriguing to note that enforced expression of
caveolin results in de-sensitization of cells towards
TRAIL as engagement of TRAIL with its respective
receptor DR4 reduces the localization of DR4 in caveolae
and results in its internalization. Obstruction of caveolae-
mediated internalization of DR4 by filipin III outstandingly
improved TRAIL-induced apoptosis [38].
Post translational modifications of proteins underpin
membrane-protein association and influence protein
trafficking, stability or aggregation, thus playing an
important role in protein signalling. In accordance with
this assumption recent data suggests that DR4 is palmi-
toylated, whereas DR5 and TNFR1 are not. In addition,
DR4 palmitoylation is essential for its raft localization
and its ability to undergo oligomerization [39].
Consistently, Ursodeoxycholic acid (UDCA) triggered
formation of lipid rafts via ROS production/PKCδ
activation pathway that played fundamental roles in
UDCA-induced apoptosis. Lipid rafts are essential not
only for provision of a platform for DR5 action but also
for regulation of DR5 expression [10]. Taken together,
epirubicin also significantly augmented lipid raft DR4
and DR5 aggregation, alongwith the localization of DR4
and DR5 in the lipid rafts [40].
While drawing a parallel between adherent and
detachment cells apoptosis assay revealed that detached
cells are more sensitive to DR5 antibody-induced apop-
tosis than adherent cells. As transition from adhesion to
detachment of EC9706 cells results in DR5 relocaliza-
tion, and enhances cytoplasmic translocation of DR5 to
cell surfaces via a Golgi-dependent pathway [41].
Cellular organelles in the endocytic pathways have a
characteristic spatial distribution and communicate
through a highly structured system of vesiculo-tubular
transport. TRAPP proteins harmonize consecutive stages
of transport, such as vesicle formation, vesicle motility
and tethering of vesicles to their target compartment.
These protein complexes are well compartmentalized in
organelle membranes, making them exceptional media-
tors for determining transport specificity.
A study delineating localization patterns of the recep-
tors in melanoma cells by confocal microscopy suggested
that TRAIL-R1 and R2 were located in the trans-Golgi
network, but the inhibitory receptors TRAIL-R3 and -R4
were located in the nucleus Figure 2. Signals from
TRAIL-R1 and -R2 tactfully triggered redistribution of
TRAIL-R3 and -R4. It was suggested by the studies thatcells that represented only TRAIL-R3 receptors and not
TRAIL-R1 or -R2 did not undergo repositioning from
the nucleus and was verified by use of mAbs which
blocked interaction of TRAIL with TRAIL-R1 and -R2.
On the contrary, in one cell line which expressed only
TRAIL-R2 and -R3 the redistribution of R3 was com-
pletely inhibited by mAb against TRAIL-R2. In the simi-
lar manner, in a line (Me4405) which expressed all
TRAIL-R, inhibition of TRAIL-R2 alone was insufficient
to stop relocation of TRAIL-R3 and -R4, and it was also
essential to inhibit TRAIL-R1. These results documented
that the signals for relocation of the decoy receptors are
dependent on signal transduction cascades from TRAIL-
R1 or -R2. [42]. Additionally, there are some other regu-
lators which mediate trafficking of death receptors to cell
surface. It has presently been recognized that golgi-spe-
cific Asp-His-His-Cys (DHHC) zinc finger protein
(GODZ) regulates TRAIL/DR4-mediated apoptosis.
Studies indicated that GODZ made its attachment to
DR4, but not to DR5, through the DHHC and the C-ter-
minal transmembrane domain. Moreover, GODZ trig-
gered localization of DR4 to the plasma membrane (PM)
via DHHC motif as proof of concept was provided by
mutation studies which confirmed that introduction of
mutation into the cysteine-rich motif of DR4 resulted in
its mistargeting and attenuated TRAIL- or GODZ-
mediated apoptosis [43].
The signal recognition particle complex (SRP) is a
molecular machinery of the “signal hypothesis” that is
contributory in protein sorting through the secretory
pathway. Similarly, experiments demonstrated that ex-
pression of the signal recognition particle (SRP) complex
was vital for apoptosis mediated by DR4, but not DR5.
Targeted inhibition of SRP subunits by RNA interference
resulted in a remarkable decrease in cell surface DR4
receptors that interrelated with inhibition of DR4-
dependent cell death. Expression of cell surface DR4 was
severely repressed in cells lacking expression of SRP54
or SRP72 [44]. Membrane proteins are embedded into
the endoplasmic reticulum (ER) by highly precise and
orchestrated pathway. It is imperative to detect that co-
translational pathway uses signal recognition particle
(SRP) and its receptor for targeting and the SEC61 trans-
locon for membrane integration. It is appealing to con-
sider that translational pathway uses an entirely different
set of factors involving transmembrane domain (TMD)-
selective cytosolic chaperones and an accompanying re-
ceptor at the ER with reference to death receptor. Clarifi-
cation of the structural and mechanistic beginning and
intricacy of this post-translational death receptor protein
insertion pathway will doubtlessly highlight some more
unexplained facts.
It is imperative to explore whether DR4 is indeed
translocated to the Golgi and the impairment of
Figure 2 Various routes of translocation of death receptors and decoy receptors towards cell surface.
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membrane is a secondary effect of SRP depletion. Like-
wise, it will be essential to find out how DR4 and other
proteins are translocated to the Golgi and whether these
events are dependent on chaperones or the ER.
Keeping in view the trafficking of receptors from endo-
plasmic reticulum to golgi and later to plasma membrane is
a well organized mechanism. We have several hints of pro-
tein complexes which might play a role in the translocation.
TRAPP proteins are identified to be component of a large
multi-protein complex involved in ER-to-Golgi and intra-
Golgi trafficking. Details were comprehensively reviewed by
[45]. For instance, TRAPPCI is necessary for the recruit-
ment of ER-derived vesicles to the cis-Golgi. Another pro-
tein, TRAPPC4 may play a role in nucleocytoplasmic
transport in colorectal cancer as enforced expression of
TRAPPC4 correspondingly enhanced activation ERK1/2
and its consequent movement into the nucleus [46].
Recent molecular genetics study indicated that
TRAPPC9 encoded the NIK- and IKK-beta-binding pro-
tein (NIBP) [47]. NIBP interacted with NIK, IKK(beta),
but not IKK(alpha) or IKK(gamma). Moreover enforced
expression of NIBP potentiated tumor necrosis factor-
alpha-induced NF-kappaB activation through augmented
phosphorylation of the IKK complex and its downstream
I(kappa)B(alpha) and p65 substrates. On the contrary,impairment of NIBP expression reduced tumor necrosis
factor-alpha-induced NF-kappaB activation and decreased
Bcl-xL gene expression in cancer cells [48].
It is indubitable that despite tremendous information
added into the developing landscape of death receptor traf-
ficking pathways many protein complexes and assemblies
are still lost and a better concept of multi-component,
multi-layered trafficking pathway is required. How TRAPP
proteins interact with death receptors and facilitate or re-
press migration from endoplasmic reticulum to golgi and
further towards plasma membrane is a missing link. As a
consequence, supplementary structure-function studies will
be needed to describe the particular sequences necessary
for DR4 cell surface localization. In this regard, how DR5
and other TNF family receptors find their way to the
plasma membrane remains fascinating, yet an outstanding
and under-defined question.
Accumulating evidence using confocal microscopy sug-
gested that DR5 were localized in the nucleus in HeLa
and HepG2 cells. Nuclear trafficking of DR5 was inhib-
ited in the cells deficient for importin β1 however
enforced expression of importin β1 restored redistribu-
tion of DR5 in nucleus [49]
It is imperative to note that certain viral proteins coun-
teract killing through death receptors by maximizing
internalization and degradation. In agreement with this
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proteins, named RID suppressed TRAIL-induced apop-
tosis of infected human cells. RID promoted endocytosis
of TRAIL-R1 from the cell surface, as indicated by flow
cytometry and indirect immunofluorescence studies for
TRAIL-R1. TRAIL-R1 was internalized in discrete vesicles
and degradation of TRAIL-R1 was noted [50].
Correspondingly, localization of DR4 but not DR5 in
lipid rafts was mediated by TRAIL and fludarabine treat-
ment [51].
It is also necessary to make a note of Nitrosylcobalamin
(NO-Cb) that inhibits survival signaling by enhancing drug
efficacy by preventing concomitant activation of negative
regulators of apoptosis (NF-kappaB or AKT). Additionally,
use of NO-Cbl and Apo2L/TRAIL represents a promising
anti-cancer combinatorial drug because DR4 (TRAIL R1)
is S nitrosylated following NO-Cbl treatment. S-nitrosyla-
tion at cysteine 304 facilitates relocalization of Fas to lipid
rafts, formation of the death-inducing signalosome, and in-
duction of cell death[52-55].Conclusions
It is undeniable that nutrigenomics has emerged as an
important facet of molecular biology and employs high-
throughput genomics technologies to disentangle how
nutrients modulate gene and protein expression and
eventually influence cellular and organism metabolism. It
is vital to use and integrate nutrigenomics in all future nu-
trition studies portray broader landscape for evidence-
based nutrition in near future. Concordant with same
viewpoint, whole-genome sequencing is possible, compre-
hensive strategies for integrating genomic data and coun-
seling of patients need to be developed.
Incontrovertibly, vitamins exert pleiotrophic responses
in malignant cells leading to cell cycle arrest, differenti-
ation, and apoptosis. Apart from their implications in
killing cancer cells via apoptosis, vitamins regulate ex-
pression of genes involved in cell proliferation and cell
death in a "subapoptotic" manner. For instance, these
vitamins mediate the cell cycle machinery, resulting in
cell cycle arrest. We have elucidated an overview of co-
operative antitumor effect when vitamins are combined
with immunological agents. Vitamins and TRAIL syner-
gize to kill cancer cells either by stimulating the expres-
sion or appearance of death receptors on cell surface
respectively or by amplifying the mitochondrial apoptotic
pathway without being toxic to normal cells. Lipophilic
vitamins are being explored for their anticancer proper-
ties by many researchers [56]. Silica nanoparticles are
also a worthwhile addition in medicine [57]. Moreover it
is important to outline those proteins which negatively
modulate anti-apoptotic proteins like TRIM32 which
degrades X-linked inhibitor of apoptosis (XIAP) andsensitizes cells to tumor necrosis factor (TNFα)-induced
apoptosis.
It is significant that a single-agent 'magic' pill for
chemoprevention is not highly effective and that using
different combinations of phytochemicals and vitamins
may be the answer.
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